Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights from a Large-Scale Real-World Chinese Cohort.
INTRODUCTION: Methylthioadenosine phosphorylase (MTAP) loss is a frequent genomic event in non-small cell lung cancer (NSCLC), yet its clinical and therapeutic implications in oncogene-driven disease remain incompletely defined. Combined MTAP/CDKN2A analysis revealed a prognostic gradient, with dual loss conferring the worst outcomes and remaining an independent predictor in multivariable models.
INTRODUCTION: Methylthioadenosine phosphorylase (MTAP) loss is a frequent genomic event in non-small cell lung cancer (NSCLC), yet its clinical and therapeutic implications in oncogene-driven disease remain incompletely defined. Combined MTAP/CDKN2A analysis revealed a prognostic gradient, with dual loss conferring the worst outcomes and remaining an independent predictor in multivariable models.
What the study was
- Study design
- Cohort study
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Why it surfaced
Relevant Precision oncology and genomic medicine study (near-term clinical implementability) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.